Histone deacetylase inhibitors as anti-neoplastic agents.

[1]  C. Blanke,et al.  Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336) , 2009, Investigational New Drugs.

[2]  David D. Smith,et al.  A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study , 2008, Clinical Cancer Research.

[3]  G. Giaccone,et al.  Histone deacetylase inhibitors in cancer therapy , 2008, Current opinion in oncology.

[4]  Razelle Kurzrock,et al.  Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers , 2008, Clinical Cancer Research.

[5]  P. Atadja,et al.  Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. , 2008, Blood.

[6]  I. Christensen,et al.  Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma , 2008, Histopathology.

[7]  I. Christensen,et al.  A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia , 2008, European journal of haematology.

[8]  E. Seto,et al.  Lysine acetylation: codified crosstalk with other posttranslational modifications. , 2008, Molecular cell.

[9]  M. Minden,et al.  Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. , 2008, Blood.

[10]  P. Atadja,et al.  Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma , 2008, Clinical Cancer Research.

[11]  J. Shen,et al.  Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. , 2008, Cancer research.

[12]  R. Bociek,et al.  Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL) , 2008 .

[13]  Suzanne F. Jones,et al.  A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors , 2008 .

[14]  H. Mackay,et al.  A phase II trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial , 2008 .

[15]  R. Glasspool,et al.  Phase II multicenter trial of the histone deactylase inhibitor (HDACi) belinostat, carboplatin and paclitaxel (BelCaP) in patients (pts) with relapsed epithelial ovarian cancer (EOC) , 2008 .

[16]  S. Bates,et al.  Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers , 2008 .

[17]  P. Munster,et al.  Phase II trial of vorinostat, a histone deacetylase inhibitor to restore the hormone sensitivity to the anti-estrogen tamoxifen in patients with advanced breast cancer having failed prior aromatase inhibitor therapy , 2008 .

[18]  C. Kortsik,et al.  Randomized phase II trial of two dosing schedules of BI 2536, a novel Plk-1 inhibitor, in patients with relapsed advanced or metastatic non-small-cell lung cancer (NSCLC) , 2008 .

[19]  Yi Tang,et al.  Acetylation Is Indispensable for p53 Activation , 2008, Cell.

[20]  C. Paweletz,et al.  Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. , 2008, Cancer research.

[21]  S. Modesitt,et al.  A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[22]  E. D. Jacobsen,et al.  Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  M. Carducci,et al.  Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Van Cutsem,et al.  Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer , 2008, Investigational New Drugs.

[25]  K. Sakamoto,et al.  Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. , 2008, Cancer research.

[26]  P. Pandolfi,et al.  Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes , 2008, Clinical Cancer Research.

[27]  Robert Brown,et al.  A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors , 2008, Clinical Cancer Research.

[28]  V. Papadimitrakopoulou,et al.  Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer , 2008, Investigational New Drugs.

[29]  H. Kantarjian,et al.  A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia. , 2007 .

[30]  R. Bernards,et al.  A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors , 2007, Proceedings of the National Academy of Sciences.

[31]  H. Hurwitz,et al.  Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors , 2007 .

[32]  Jorge Cortes,et al.  Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. , 2007, Blood.

[33]  P. Marks,et al.  Histone deacetylase inhibitors: molecular mechanisms of action , 2007, Oncogene.

[34]  T. Kuzel,et al.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Steinberg,et al.  Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin , 2007, Clinical Cancer Research.

[36]  P. Munster,et al.  Phase I/II trial combining the HDAC inhibitor, valproic acid (VPA) and FEC100 (5-fluorouracil, epirubicin and cyclophosphamide) in locally advanced/metastatic breast cancer , 2007 .

[37]  M. Janicot,et al.  A first-in-man phase I study of R306465, a histone deacetylase (HDAC) inhibitor exploring pharmacokinetics (PK) and pharmacodynamics (PD) utilizing an electrochemiluminescent immunoassay in patients (p) with advanced tumours , 2007 .

[38]  J. Buckner,et al.  N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM) , 2007 .

[39]  David C. Smith,et al.  Suberoylanilide hydroxamic acid (vorinostat) post chemotherapy in hormone refractory prostate cancer (HRPC) patients (pts): A phase II trial by the Prostate Cancer Clinical Trials Consortium (NCI 6862) , 2007 .

[40]  S. Ramalingam,et al.  Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies , 2007, Clinical Cancer Research.

[41]  M. Fishman,et al.  Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Mark J. Smyth,et al.  Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma , 2007, Proceedings of the National Academy of Sciences.

[43]  S. Baylin,et al.  Stem Cell Chromatin Patterns: An Instructive Mechanism for DNA Hypermethylation? , 2007, Cell cycle.

[44]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[45]  Michael Rytting,et al.  Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.

[46]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[47]  K. Bhalla,et al.  A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies , 2006, Clinical Cancer Research.

[48]  T. Fojo,et al.  Challenges of Evaluating the Cardiac Effects of Anticancer Agents , 2006, Clinical Cancer Research.

[49]  M. Grever,et al.  Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors , 2006, Clinical Cancer Research.

[50]  R. Sullivan,et al.  Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  A. Hauschild,et al.  A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  S. Ramalingam,et al.  Phase I study of vorinostat, a histone deacetylase (HDAC) inhibitor, in combination with carboplatin (Cb) and paclitaxel (P) for patients with advanced solid malignancies (NCI #6922). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  M. Grever,et al.  Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. , 2006, Cancer research.

[54]  W. Stadler,et al.  A phase II study of depsipeptide in refractory metastatic renal cell cancer. , 2006, Clinical genitourinary cancer.

[55]  J. Issa,et al.  Review: recent clinical trials in epigenetic therapy. , 2006, Reviews on recent clinical trials.

[56]  Y. Bang,et al.  Histone Deacetylase Inhibitors for Cancer Therapy , 2006, Epigenetics.

[57]  M. Duvic,et al.  Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. , 2005, The Journal of investigative dermatology.

[58]  M. Toyota,et al.  Epigenetic changes in solid and hematopoietic tumors. , 2005, Seminars in oncology.

[59]  L. Schwartz,et al.  Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  G. Perez,et al.  Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[61]  M. Grever,et al.  A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. , 2004, Blood.

[62]  U. Germing,et al.  Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. , 2004, Blood.

[63]  H. Keer,et al.  Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. , 2004, Lung cancer.

[64]  S. Bates,et al.  A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. , 2004, Current pharmaceutical design.

[65]  P. Dent,et al.  Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. , 2003, Cancer research.

[66]  Stuart L Schreiber,et al.  Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[67]  J. Issa,et al.  Critical Role of Histone Methylation in Tumor Suppressor Gene Silencing in Colorectal Cancer , 2003, Molecular and Cellular Biology.

[68]  J. Marshall,et al.  A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. , 2002, Journal of experimental therapeutics & oncology.

[69]  S. Bates,et al.  Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[70]  W. Wilson,et al.  Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. , 2001, Blood.

[71]  M. Guenther,et al.  Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen* , 2001, The Journal of Biological Chemistry.

[72]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[73]  C. Allis,et al.  Histone methylation versus histone acetylation: new insights into epigenetic regulation. , 2001, Current opinion in cell biology.

[74]  E. Olson,et al.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.

[75]  M. Grever,et al.  Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. , 2009, The Journal of clinical endocrinology and metabolism.

[76]  David Horn,et al.  Histone deacetylases. , 2008, Advances in experimental medicine and biology.

[77]  Chunlei Zhang,et al.  Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.

[78]  A. Zelenetz,et al.  Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.